June 14, 2022
Daiichi Sankyo’s FLT3 inhibitor quizartinib demonstrated a reduction of 22.4% in the risk of deaths versus chemotherapy alone when used for the first-line treatment of FLT3-ITD positive acute myeloid leukemia (AML), the latest PIII data show. The Japanese drug maker...read more